1. Quotes

    1-10 of 725 1 2 3 4 ... 71 72 73 »
    1. Publisher: Optical Coherence Tomography News
      This latest innovation from Bioptigen enables faster alignment, targeted explorations, and brilliant visualizations, while simultaneously viewing both OCT and color fundus images in real time...We expect this capability will be impactful not only for mouse and rat research, but also for handheld, dual-modality imaging of larger animals including cats, dogs, rabbits, and non-human primates," Buckland added. Bioptigen has begun producing and shipping the new multimodality systems from the company's North Carolina operations center, and will showcase the product at ARVO 2014 in Orlando, May 4-8.
      - Eric L. Buckland in Bioptigen Introduces Image-Guided SDOCT Technology to Advance Preclinical Eye Research
    2. Publisher: Optical Coherence Tomography News
      This latest innovation from Bioptigen enables faster alignment, targeted explorations, and brilliant visualizations, while simultaneously viewing both OCT and color fundus images in real time
      - In Bioptigen Introduces Image-Guided SDOCT Technology to Advance Preclinical Eye Research
    3. Publisher: Electronic Engineering Times Europe
      Currently available imaging equipment such as computer tomography or magnetic resonance tomography does not help us to analyse processes at the cell level like vascular deposits
      - In Biomedical sensors analyse vascular deposits
    4. Publisher: Optical Coherence Tomography News
      It was a difficult decision but after numerous attempts by many dedicated people our ability to turn Imalux into an on-gong business was just not going to happen. The decision to cease operations is closely related to the significant financing challenges faced by early stage medical device companies in general and imaging companies specifically. It is unfortunate we closed the business but both current and past members of our team can be proud of all that was accomplished in trying to bring a new imaging technology to market. At some point there is little doubt our pioneering technology will be clinically adopted on a large scale in medicine. We thank our customers, investors and partners for their support and assistance over the years.
      - James M. Fulton in Imalux Ceases Operation
    5. Publisher: Optical Coherence Tomography News
      We are pleased to have this clearance, and confident the results reflect the quality of our diagnostic tools in imaging that assist doctors in diagnosing ocular diseases
      - In NIDEK Announces FDA Clearance of the RS-3000 Advance
    6. Publisher: Optical Coherence Tomography News
      Miniaturization of OCT-based imaging technology on integrated photonics enables a novel, unique generation of not only cost-effective, but also compact, robust and nearly maintenance-free handheld OCT systems...The partners of the BiopsyPen Project have exquisite complementary expertise to accomplish a significant step towards this ambitious goal.”
      - Wolfgang Drexler in MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding; Initiative Aimed at New Clinical Applications for Optical Coherence Tomography
    7. Publisher: Optical Coherence Tomography News
      This unique collaboration of leading European technology and clinical centers will allow us to significantly extend the technical possibilities and clinical indications of our micro-chip based OCT system
      - Eduardo Margallo Balbás in MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding; Initiative Aimed at New Clinical Applications for Optical Coherence Tomography
    8. Publisher: Optical Coherence Tomography News
      The positive results from our study clearly demonstrate the clinical benefits of using our VivoSight OCT system in the diagnosis and monitoring of basal cell carcinoma. We believe that VivoSight has the potential to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect the skin, and in particular non-melanoma skin cancers. We look forward to releasing the full data in due course.
      - Jon Holmes in Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT
    9. Publisher: Optical Coherence Tomography News
      The NvisionVLE Imaging System is an exciting new imaging technology that is enabling physicians to visualize esophageal abnormalities at and below the mucosal surface, helping inform clinical decision-making... “With new hospitals adopting the technology every month, and with the support of our investors and strategic guidance of our board, we can continue to expand our sales force to facilitate the adoption of NvisionVLE at more centers. Hospitals from New England, to Florida, to California are already offering this advanced imaging technology. We will continue to build out our operational capacity to meet the increasing demand for our products, while also working on new features and product offerings for the future.
      - Charles Carignan in NinePoint Medical Completes $34 Million Series B Financing to Expand Commercialization of its Breakthrough NvisionVLE™ Imaging System
    10. Publisher: Optical Coherence Tomography News
      The NvisionVLE Imaging System is an exciting new imaging technology that is enabling physicians to visualize esophageal abnormalities at and below the mucosal surface, helping inform clinical decision-making.
      - Charles Carignan in NinePoint Medical Completes $34 Million Series B Financing to Expand Commercialization of its Breakthrough NvisionVLE™ Imaging System
    1-10 of 725 1 2 3 4 ... 71 72 73 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources, Velocimetry
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Most Quoted Topics